365 related articles for article (PubMed ID: 34297922)
1. Multi-omics reveal microbial determinants impacting responses to biologic therapies in inflammatory bowel disease.
Lee JWJ; Plichta D; Hogstrom L; Borren NZ; Lau H; Gregory SM; Tan W; Khalili H; Clish C; Vlamakis H; Xavier RJ; Ananthakrishnan AN
Cell Host Microbe; 2021 Aug; 29(8):1294-1304.e4. PubMed ID: 34297922
[TBL] [Abstract][Full Text] [Related]
2. Gut Microbiome Function Predicts Response to Anti-integrin Biologic Therapy in Inflammatory Bowel Diseases.
Ananthakrishnan AN; Luo C; Yajnik V; Khalili H; Garber JJ; Stevens BW; Cleland T; Xavier RJ
Cell Host Microbe; 2017 May; 21(5):603-610.e3. PubMed ID: 28494241
[TBL] [Abstract][Full Text] [Related]
3. Metabolic Functions of Gut Microbes Associate With Efficacy of Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases.
Aden K; Rehman A; Waschina S; Pan WH; Walker A; Lucio M; Nunez AM; Bharti R; Zimmerman J; Bethge J; Schulte B; Schulte D; Franke A; Nikolaus S; Schroeder JO; Vandeputte D; Raes J; Szymczak S; Waetzig GH; Zeuner R; Schmitt-Kopplin P; Kaleta C; Schreiber S; Rosenstiel P
Gastroenterology; 2019 Nov; 157(5):1279-1292.e11. PubMed ID: 31326413
[TBL] [Abstract][Full Text] [Related]
4. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice.
Gisbert JP; Chaparro M
J Crohns Colitis; 2020 Jun; 14(5):694-709. PubMed ID: 31777929
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis.
Peyrin-Biroulet L; Arkkila P; Armuzzi A; Danese S; Guardiola J; Jahnsen J; Lees C; Louis E; Lukáš M; Reinisch W; Roblin X; Jang M; Byun HG; Kim DH; Lee SJ; Atreya R
BMC Gastroenterol; 2022 Jun; 22(1):291. PubMed ID: 35676620
[TBL] [Abstract][Full Text] [Related]
6. Targeted
Notararigo S; Martín-Pastor M; Viñuela-Roldán JE; Quiroga A; Dominguez-Munoz JE; Barreiro-de Acosta M
J Mol Med (Berl); 2021 Sep; 99(9):1251-1264. PubMed ID: 34021361
[TBL] [Abstract][Full Text] [Related]
7. Higher Intra-Abdominal Visceral Adipose Tissue Mass Is Associated With Lower Rates of Clinical and Endoscopic Remission in Patients With Inflammatory Bowel Diseases Initiating Biologic Therapy: Results of the Constellation Study.
Yarur AJ; Bruss A; Moosreiner A; Beniwal-Patel P; Nunez L; Berens B; Colombel JF; Targan SR; Fox C; Melmed GY; Abreu MT; Deepak P
Gastroenterology; 2023 Oct; 165(4):963-975.e5. PubMed ID: 37499955
[TBL] [Abstract][Full Text] [Related]
8. Integrated multi-omics reveal gut microbiota-mediated bile acid metabolism alteration regulating immunotherapy responses to anti-α4β7-integrin in Crohn's disease.
Han B; Tang D; Lv X; Fan J; Li S; Zhu H; Zhang J; Xu S; Xu X; Huang Z; Huang Z; Lin G; Zhan L; Lv X
Gut Microbes; 2024; 16(1):2310894. PubMed ID: 38312103
[TBL] [Abstract][Full Text] [Related]
9. Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission.
Wang Y; Wang J; Pekow J; Dalal S; Cohen RD; Ollech J; Israel A; Shogan BD; Micic D; Cannon L; Umanskiy K; Hurst R; Hyman N; Rubin DT; Sakuraba A
J Gastroenterol Hepatol; 2019 Dec; 34(12):2090-2095. PubMed ID: 31169926
[TBL] [Abstract][Full Text] [Related]
10. Biologic therapies in inflammatory bowel disease.
Cohen LB; Nanau RM; Delzor F; Neuman MG
Transl Res; 2014 Jun; 163(6):533-56. PubMed ID: 24467968
[TBL] [Abstract][Full Text] [Related]
11. Multi-"-Omics" Profiling in Patients With Quiescent Inflammatory Bowel Disease Identifies Biomarkers Predicting Relapse.
Borren NZ; Plichta D; Joshi AD; Bonilla G; Sadreyev R; Vlamakis H; Xavier RJ; Ananthakrishnan AN
Inflamm Bowel Dis; 2020 Sep; 26(10):1524-1532. PubMed ID: 32766830
[TBL] [Abstract][Full Text] [Related]
12. Donor Species Richness Determines Faecal Microbiota Transplantation Success in Inflammatory Bowel Disease.
Vermeire S; Joossens M; Verbeke K; Wang J; Machiels K; Sabino J; Ferrante M; Van Assche G; Rutgeerts P; Raes J
J Crohns Colitis; 2016 Apr; 10(4):387-94. PubMed ID: 26519463
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal Trajectory of Fatigue With Initiation of Biologic Therapy in Inflammatory Bowel Diseases: A Prospective Cohort Study.
Borren NZ; Tan W; Colizzo FP; Luther J; Garber JJ; Khalili H; van Der Woude CJ; Ananthakrishnan AN
J Crohns Colitis; 2020 Mar; 14(3):309-315. PubMed ID: 31504365
[TBL] [Abstract][Full Text] [Related]
14. Factors influencing the outcome of vedolizumab treatment: Real-life data with objective outcome measurements.
Mader O; Juillerat P; Biedermann L; Michetti P; Hruz P; Pittet V; Rogler G; Zahnd-Straumann N; Seibold F
United European Gastroenterol J; 2021 Apr; 9(3):398-406. PubMed ID: 33203339
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials.
Ben-Horin S; Novack L; Mao R; Guo J; Zhao Y; Sergienko R; Zhang J; Kobayashi T; Hibi T; Chowers Y; Peyrin-Biroulet L; Colombel JF; Kaplan GG; Chen MH
Gastroenterology; 2022 Feb; 162(2):482-494. PubMed ID: 34757139
[TBL] [Abstract][Full Text] [Related]
16. Dysbiosis and Associated Stool Features Improve Prediction of Response to Biological Therapy in Inflammatory Bowel Disease.
Caenepeel C; Falony G; Machiels K; Verstockt B; Goncalves PJ; Ferrante M; Sabino J; Raes J; Vieira-Silva S; Vermeire S
Gastroenterology; 2024 Mar; 166(3):483-495. PubMed ID: 38096956
[TBL] [Abstract][Full Text] [Related]
17. Allergic and Immunologic Perspectives of Inflammatory Bowel Disease.
Clarke K; Chintanaboina J
Clin Rev Allergy Immunol; 2019 Oct; 57(2):179-193. PubMed ID: 29754190
[TBL] [Abstract][Full Text] [Related]
18. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
19. [Current concepts about the treatment of inflammatory bowel disease, biological therapy].
Bosques-Padilla FJ; Galindo-Marines SL; Yamamoto-Farusho JK
Rev Gastroenterol Mex; 2008; 73(4):217-30. PubMed ID: 19666271
[TBL] [Abstract][Full Text] [Related]
20. Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre.
Kolar M; Duricova D; Bortlik M; Hruba V; Machkova N; Mitrova K; Malickova K; Lukas M; Lukas M
Dig Dis; 2017; 35(1-2):91-100. PubMed ID: 28147356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
